Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Body Mass Index ≥ 27

• Status: Completed
• Trial end date: 2015-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to determine whether administration of 150 mg clopidogrel is effective in reducing the one-year incidence of thromboischemic events in patients with high on-clopidogrel platelet reactivity compared to 75 mg clopidogrel in the patient population overweight or obese with a body mass index (BMI) ≥ 27 kg.m-2.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Les Laboratoires des Médicaments Stériles
• Collaborator: University Hospital Fattouma Bourguiba
• Treatments: Clopidogrel; Ticlopidine

Criteria

Inclusion Criteria:

• Male or female,

• Old (e) of more than 20 years

• BMI ≥ 27kg.m-2

• Patients hospitalized for acute coronary syndrome (Whatever the ST segment and troponin dosage)

• Patients with proven coronary candidates for treatment with Clopidogrel (who received a loading dose of 600mg over 2 hours or treated with 75 mg/day or 150mg / day of clopidogrel for longer than 7 days)

Exclusion Criteria:

• Patients unwilling.

• Patient participating in another study.

• Patients with cardiogenic shock

• Patient on anti GpIIbIIIa or stopped less than 72 hours before the test aggregability

• Patients scheduled for surgery in less than 6 months

• ischemic stroke older than 6 weeks.

• History of hemorrhagic stroke (any time)

• Patients on or candidates for AVK

• Patients with a different anti ADP (ticlopidine, prasugrel)

• Patients with an indication against clopidogrel (side effects, bleeding ...)

• Thrombocytopenia < 100000/mm3

• anemia (Ht < 30%)

• Thrombocythaemia (Ht > 52%)

• Pregnancy